BACKGROUND AND OBJECTIVES: We conducted a phase II study using @entity3003 and @entity2879 on @entity1 with recurrent @entity11 to investigate @entity5 response. METHODS: From January 1995 to March 1997, 21 @entity1 with recurrent @entity11 were treated with a @entity3003 (300 mg/m(2), day 1)/ @entity2879 (100 mg/m(2), days 1-3) regimen every 3-4 weeks. The following radiologic parameters were evaluated: @entity5 size, central lucency, degree of contrast enhancement, and mass effect. No @entity1 had received chemotherapy previously. Dose escalation corresponded to hematologic tolerance and to general and neurologic performance status. Most @entity1 were treated postoperatively with involved field radiotherapy followed by a boost to the @entity5 area, as defined on the presurgery computed tomography scan or on magnetic resonance imaging. Mean interval to introduction of chemotherapy was 8.8 months (range, 7-36 months). @entity1 received a mean of four cycles [range, 2-8 cycles]. RESULTS: Only 2 @entity1 showed moderate radiological response, while 12 @entity1 died of progressive disease. Mean time to progression following discontinuation of chemotherapy was 5.8 months (range, 1-11 months). The other @entity1 survived with persistent disease and are being treated palliatively. @entity137 was manageable (1, @entity1398 ; 1, @entity882 (45,000/mm(3)); 2, temporarily elevated transaminase level; 2, @entity134 -induced @entity3621 ). CONCLUSIONS: This phase II regimen proved to be ineffective in recurrent @entity11 . Further studies incorporating innovative drug regimens and schedules are warranted. J. Surg. Oncol., 1999;71:167-170.

@entity3003 and XXXX for recurrent @entity11 following surgical and radiotherapy failure: A clinical study conducted at the Northern Israel Oncology Center.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity11 :: ('MESH:D005910', 'Disease') :: ['malignant glioma'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenic sepsis'] @entity3621 :: ('MESH:D005756', 'Disease') :: ['erosive gastritis']
@entity2879 :: (MESH:D005047,Chemical) :: ['etoposide']
